Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 586 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Test solution Clear all
Terminated Phase 1 Interventional Results available

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

NCT03604445
View directory record Official record
Conditions
Neoplasms
Interventions
BI 905677
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT05109234
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam Film-coated tablet, Brivaracetam oral solution
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years to 26 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Birmingham, Alabama • Orange, California • Augusta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 25, 2026, 11:40 AM EDT
Terminated Not applicable Interventional Results available

Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus

NCT03560609
View directory record Official record
Conditions
Keratoconus, Glaucoma
Interventions
Ophthalmodynamometer, Goldmann applanation tonometer, Pentacam, ORA, Optical Coherence Tomography (OCT)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 25, 2026, 11:40 AM EDT
Active, not recruiting Phase 3 Interventional

Optimizing Tobacco Use Treatment for PLWHA

NCT04176172
View directory record Official record
Conditions
HIV/AIDS, Nicotine Dependence
Interventions
Varenicline, Nicotine patch, Standard treatment, Standard treatment + Managed Problem Solving (MAPS) adherence intervention
Drug · Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects

NCT02806219
View directory record Official record
Conditions
Healthy
Interventions
Prefilled syringe (PFS), e-Device
Device
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males

NCT00493311
View directory record Official record
Conditions
Fever
Interventions
IV Placebo, IV Acetaminophen, Reference Standard Endotoxin (RSE)
Drug · Biological
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Not applicable Interventional Results available

Web Based Tools to Improve Medication Continuity in Adolescents With ADHD

NCT04386096
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Adherence, Medication
Interventions
Mehealth for ADHD software with medication continuity tools, Mehealth for ADHD software with no medication continuity tools
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 15 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 25, 2026, 11:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Myocardial Perfusion and Fibrosis in Cancer Survivors

NCT03191461
View directory record Official record
Conditions
Myocardial Fibrosis, Myocardial Injury, Chemotherapeutic Toxicity
Interventions
Adenosine stress test MRI
Diagnostic Test
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System

NCT06261905
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
[11C]-PHNO, Calcitriol, Placebo Control, PET Scan
Drug · Dietary Supplement · Other + 1 more
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242

NCT02824666
View directory record Official record
Conditions
Schizophrenia
Interventions
ATI-9242, [18F]Fallypride Imaging
Drug · Radiation
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Skin Safety Study to Evaluate the Irritation Potential in Healthy Volunteers

NCT02227069
View directory record Official record
Conditions
Healthy Volunteers
Interventions
M518101, M518101 Vehicle, sodium lauryl sulfate, saline
Drug · Other
Lead sponsor
Maruho North America Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 25, 2026, 11:40 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate Efficacy and Safety of a New Suffocating Head Lice Product.

NCT05378477
View directory record Official record
Conditions
Head Lice, Pediculosis Capitis
Interventions
X92001752, RID Super Max Solution, Nix Crème, Pouxit Végétal
Device · Drug
Lead sponsor
Oystershell NV
Industry
Eligibility
1 Year and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Not applicable Interventional

Scleral Contact Lens Insertion Solution Study

NCT03612284
View directory record Official record
Conditions
Irregular; Contour of Cornea
Interventions
contact lens insertion solution
Device
Lead sponsor
Jennifer Fogt
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 25, 2026, 11:40 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

NCT01437878
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Interventions
Iloprost, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
40 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
9
States / cities
Torrance, California • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Phase 1 Interventional

A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia

NCT03399084
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric carboxymaltose
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women

NCT07542847
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OPC-167832, Itraconazole, Carbamazepine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 25, 2026, 11:40 AM EDT
Completed No phase listed Observational

Biological Determinants of Peritoneal Dialysis

NCT02694068
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Peritoneal Equilibrium Test, 4 hour dwell of 2.5/4.25% dextrose solution
Other
Lead sponsor
University of Washington
Other
Eligibility
20 Years and older
Enrollment
4,865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 25, 2026, 11:40 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy

NCT06911372
View directory record Official record
Conditions
Gestational Diabetes Mellitus (GDM), Postpartum Women, Uncomplicated Pregnancy
Interventions
Intradermal Microdialysis, Brain Blood Flow Tests, Local Heating
Drug · Other
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 25, 2026, 11:40 AM EDT
Completed No phase listed Observational

COVID-19 Respiratory Outcomes Registry

NCT05074875
View directory record Official record
Conditions
Covid19
Interventions
Questionnaires and Patient Reported Outcomes (PROs), Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR), Blood Samples for Biomarkers, High Resolution Computed Tomography, Physical Exam and Vital Signs, Medical Research Council Sum Score, Hand Grip Strength, Spirometry, Diffusing Capacity of Carbon Monoxide, 6 Minute Walk Test, Sit to Stand (STS) Measurement
Other · Diagnostic Test · Genetic
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Timeline
2021 – 2023
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Normal Breathing and Swallowing in Healthy Volunteers

NCT03122145
View directory record Official record
Conditions
Healthy
Interventions
Capsaicin, Videofluoroscopic swallow study
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 25, 2026, 11:40 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Validation of Texture Changing Coatings for Use in At-Home Rapid Tests

NCT06539728
View directory record Official record
Conditions
Vision, Low, Blindness
Interventions
Interaction with Mock COVID-19 Rapid Antigen Test and Reference Surfaces, Biomechanical Measurements, Psychophysical Tasks
Diagnostic Test · Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 25, 2026, 11:40 AM EDT
Recruiting Not applicable Interventional

Implementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC)

NCT05664867
View directory record Official record
Conditions
Hereditary Cancer Syndrome
Interventions
Mainstream Genetic Testing Model, Enhanced Standard of Care Model
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
25 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution

NCT02298842
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Platelets stored in InterSol, Platelets stored in Plasma
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 25, 2026, 11:40 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

NCT01889186
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
Interventions
ABT-199 (Main Cohort), ABT-199 (Safety Expansion Cohort)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
16
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 25, 2026, 11:40 AM EDT